title: Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
authors.forename: Amanda K
authors.initials: AK
authors.lastname: Raymond
authors.forename: Puja K
authors.initials: PK
authors.lastname: Puri
authors.forename: M Angelica
authors.initials: MA
authors.lastname: Selim
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Tyler
authors.forename: Kelly Carter
authors.initials: KC
authors.lastname: Nelson
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000175:diagnosis; D004333:Drug Administration Routes; D005500:Follow-Up Studies; D006801:Humans; D007866:Leg; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D040262:Receptors, Vascular Endothelial Growth Factor; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D040262:Receptors, Vascular Endothelial Growth Factor